WBB Securities Reiterates Buy Rating for Cempra Inc. (CEMP)
Cempra Inc. (NASDAQ:CEMP)‘s stock had its “buy” rating reaffirmed by research analysts at WBB Securities in a research note issued on Tuesday. They presently have a $40.00 price objective on the stock. WBB Securities’ target price suggests a potential upside of 467.38% from the stock’s previous close.
Several other research analysts have also recently weighed in on CEMP. Morgan Stanley cut shares of Cempra from an “overweight” rating to an “underweight” rating and reduced their price target for the company from $35.00 to $5.00 in a report on Tuesday. Cowen and Company reiterated a “buy” rating on shares of Cempra in a report on Tuesday, August 2nd. Jefferies Group reduced their price target on shares of Cempra from $42.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, August 2nd. Needham & Company LLC reduced their price target on shares of Cempra from $36.00 to $15.00 and set a “buy” rating for the company in a report on Monday. Finally, Raymond James Financial Inc. assumed coverage on shares of Cempra in a report on Tuesday, September 13th. They issued an “outperform” rating and a $32.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $19.25.
Cempra (NASDAQ:CEMP) opened at 7.05 on Tuesday. The company’s market cap is $369.29 million. Cempra has a one year low of $5.70 and a one year high of $34.24. The company has a 50-day moving average of $20.27 and a 200 day moving average of $19.57.
Cempra (NASDAQ:CEMP) last issued its earnings results on Thursday, October 27th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.02. Cempra had a negative net margin of 678.72% and a negative return on equity of 59.94%. The firm earned $4 million during the quarter, compared to the consensus estimate of $3.90 million. During the same quarter in the prior year, the firm earned ($0.63) earnings per share. The business’s quarterly revenue was up 60.0% on a year-over-year basis. Equities research analysts predict that Cempra will post ($2.42) EPS for the current year.
Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Cempra by 0.4% in the third quarter. BlackRock Inc. now owns 4,590 shares of the company’s stock valued at $111,000 after buying an additional 17 shares during the last quarter. Legal & General Group Plc raised its position in shares of Cempra by 5.8% in the second quarter. Legal & General Group Plc now owns 7,102 shares of the company’s stock valued at $117,000 after buying an additional 391 shares during the last quarter. Advisor Group Inc. raised its position in shares of Cempra by 2,258.0% in the third quarter. Advisor Group Inc. now owns 6,508 shares of the company’s stock valued at $157,000 after buying an additional 6,232 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of Cempra during the third quarter valued at $202,000. Finally, Quantitative Investment Management LLC raised its position in shares of Cempra by 3.8% in the second quarter. Quantitative Investment Management LLC now owns 16,300 shares of the company’s stock valued at $268,000 after buying an additional 600 shares during the last quarter. 78.52% of the stock is currently owned by institutional investors.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.
Receive News & Stock Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related stocks with our FREE daily email newsletter.